[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
Eguchi
Kazuo
K
Department of Internal Medicine, Nishiarita Kyoritsu Hospital.
Kario
Kazuomi
K
Shimada
Kazuyuki
K
D000419:Albuminuria; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015415:Biomarkers; D001713:Biphenyl Compounds / Q000627:therapeutic use; D002216:Captopril / Q000627:therapeutic use; D006332:Cardiomegaly / Q000209:etiology / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D048909:Diabetes Complications; D003930:Diabetic Retinopathy / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy*; D000077405:Irbesartan; D007674:Kidney Diseases / Q000209:etiology / Q000517:prevention & control; D019808:Losartan / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D012306:Risk; D013777:Tetrazoles / Q000627:therapeutic use
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D001713:Biphenyl Compounds; D013777:Tetrazoles; D002216:Captopril; D000077405:Irbesartan; D019808:Losartan